BridgeBio Oncology announces poster presentations on innovative cancer treatments at the 2025 AACR-NCI-EORTC conference in Boston.
Quiver AI Summary
BridgeBio Oncology Therapeutics, Inc. (BBOT) announced that it will present two posters at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston from October 22-26, 2025. The first poster, presented by Dr. Carlos Stahlhut, highlights BBO-11818, a potent oral inhibitor of KRAS with strong anti-tumor activity in preclinical models. The second poster, by Dr. Kerstin Sinkevicius, discusses BBO-10203, a unique oral agent that disrupts the RAS:PI3Kα interaction, which inhibits tumor growth without causing hyperglycemia. BBOT is focused on developing new therapies targeting RAS and PI3Kα to improve patient outcomes in cancers related to these oncogenes. More information can be found on their website.
Potential Positives
- Participation in a prominent international conference (AACR-NCI-EORTC) enhances the company's visibility within the oncology and biopharmaceutical community.
- Presentation of two significant research abstracts highlights innovative drug candidates (BBO-11818 and BBO-10203) targeting KRAS mutations, demonstrating the company's commitment to advancing cancer therapeutics.
- Showcasing robust preclinical results could attract interest from potential investors and partners in the pharmaceutical industry.
- The focus on improving outcomes for cancer patients driven by prevalent oncogenes positions BBOT as a company dedicated to addressing critical medical needs in oncology.
Potential Negatives
- None
FAQ
What is the focus of BridgeBio Oncology Therapeutics, Inc.?
BridgeBio Oncology Therapeutics, Inc. focuses on RAS-pathway malignancies and developing innovative cancer therapeutics.
When will the poster presentations take place?
The poster presentations will occur on October 23 and October 25, 2025, at the AACR-NCI-EORTC Conference in Boston.
Who is presenting the BBO-11818 poster?
Carlos Stahlhut, PhD, Associate Director at BBOT, will present the BBO-11818 poster.
What is BBO-10203 in cancer therapy?
BBO-10203 is a first-in-class, orally bioavailable selective breaker of the RAS:PI3Kα interaction that inhibits tumor growth.
Where can I find more information about BBOT?
More information about BridgeBio Oncology Therapeutics can be found on their website at www.bbotx.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BBOT Analyst Ratings
Wall Street analysts have issued reports on $BBOT in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 09/15/2025
- Wedbush issued a "Outperform" rating on 08/18/2025
To track analyst ratings and price targets for $BBOT, check out Quiver Quantitative's $BBOT forecast page.
$BBOT Price Targets
Multiple analysts have issued price targets for $BBOT recently. We have seen 4 analysts offer price targets for $BBOT in the last 6 months, with a median target of $25.0.
Here are some recent targets:
- Andrew Berens from Leerink Partners set a target price of $25.0 on 09/17/2025
- Robert Burns from HC Wainwright & Co. set a target price of $27.0 on 09/15/2025
- Matthew Biegler from Oppenheimer set a target price of $23.0 on 09/04/2025
- David Nierengarten from Wedbush set a target price of $25.0 on 08/18/2025
Full Release
SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced poster presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held on October 22-26, 2025, in Boston, Massachusetts. The abstracts released today can be found on the AACR website here .
Details on the abstracts are as follows:
- Title: BBO-11818: an orally bioavailable, highly potent and selective non-covalent pan-KRAS(ON) and (OFF) inhibitor with robust anti-tumor activity in KRAS-mutant preclinical models
- Session: Poster Session A
- Session Date/Time: Thursday, October 23, from 12:30 p.m. – 4:00 p.m. ET
- Presenter: Carlos Stahlhut, PhD, Associate Director, BBOT
- Title: BBO-10203, a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction inhibits tumor growth alone and in combination with KRAS inhibitors in KRAS mutant models without inducing hyperglycemia
- Session: Poster Session C
- Session Date/Time: Saturday, October 25, from 12:30 p.m. – 4:00 p.m. ET
- Presenter: Kerstin Sinkevicius, PhD, Vice President, Pharmacology, BBOT
About BBOT
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit
www.bbotx.com
and follow us on
LinkedIn
.
BBOT Contacts:
Investor Contact:
Heather Armstrong, Head of Investor Relations
BBOT
[email protected]
Media Contact:
Jake Robison
Inizio Evoke Comms
[email protected]
